AGMB stock Statistics — Agomab Therapeutics NV filings, insiders & smart money

Price and daily changeSign in

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2025-12-31 · listed ADS: 34.16M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.10%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 2.57%
Short ratioDays to cover, as published by FINRA: 6.77
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 62.60%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 53.80%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -39.22%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -34.74%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, FY Dec 25

-143.22

EPS (fwd)

Cash & equivalentsas of Dec 25: EUR 86.41M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: EUR 1.25M
Debt / equityas of Dec 25: 0.96%
Current ratioas of Dec 25: 6.52
Quick ratio: —
Operating cash flowFY Dec 25: -EUR 51.74M
Free cash flow: —
TTM revenue / diluted share: —